SRR15030870
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.450
- G2M_CHECKPOINT+0.380
- E2F_TARGETS+0.370
- MITOTIC_SPINDLE+0.320
- WNT_BETA_CATENIN_SIGNALING+0.280
- UV_RESPONSE_UP+0.210
- CHOLESTEROL_HOMEOSTASIS+0.180
- DNA_REPAIR+0.180
- MYC_TARGETS_V1+0.160
- P53_PATHWAY+0.160
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.540
- IL6_JAK_STAT3_SIGNALING-0.420
- ALLOGRAFT_REJECTION-0.410
- INTERFERON_GAMMA_RESPONSE-0.380
- INFLAMMATORY_RESPONSE-0.360
- PROTEIN_SECRETION-0.350
- COAGULATION-0.340
- COMPLEMENT-0.330
- KRAS_SIGNALING_UP-0.320
- IL2_STAT5_SIGNALING-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | GSM6454731 | — | E | 0.890 |
| 2 | SRR6013543 | — | cohortSQ1 | 0.881 |
| 3 | BS_8SKZ7BRN | low-grade glioma | — | 0.878 |
| 4 | TCGA-56-7730-01A-11R-2125-07 | — | cohortSQ2 | 0.868 |
| 5 | TCGA-58-A46N-01A-11R-A24H-07 | — | cohortSQ2 | 0.867 |
| 6 | TCGA-LA-A446-01A-21R-A24Z-07 | — | cohortSQ2 | 0.862 |
| 7 | TCGA-94-8490-01A-11R-2326-07 | — | cohortSQ2 | 0.858 |
| 8 | TCGA-85-8072-01A-31R-2247-07 | — | cohortSQ2 | 0.855 |
| 9 | TCGA-77-8153-01A-11R-2403-07 | — | cohortSQ2 | 0.854 |
| 10 | TCGA-37-A5EL-01A-11R-A26W-07 | — | cohortSQ1 | 0.854 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.450 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.380 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.370 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.320 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.280 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.210 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.180 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.180 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.160 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.160 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.150 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.140 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.120 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.110 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.080 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.060 | Inavolisib | — uncovered |
| PEROXISOME | 0.050 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.030 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.030 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.030 | Inavolisib | — uncovered |